Navigating Recent Advances in Alzheimer’s Disease: Expert Insights on Neuropathological Diagnostic Markers and the Clinical Potential of Novel Disease-Modifying Therapies

Released On
September 14, 2022

Expires On
September 14, 2023

Media Type
Internet

Completion Time
30 minutes

Specialty
Cardiology, Case Management, Education, Ethics, Genetics, Geriatric Medicine, Home Care, Hospice, Hospitalist, Neurology, Occupational Medicine, Other, Pharmacy, Primary Care, Psychiatry, Sleep Medicine

Topic(s)
Alzheimer's, Dementia, Depression, Geriatric Medicine, Major Depression, Mental Health, Mood Disorders, Pharmacology, Sleep Medicine

Scroll to the Bottom of this Information to Begin this Course

This educational activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning.

This activity is supported by an educational grant from Lilly.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to meet the educational needs of dementia specialists, neurologists, primary care physicians, and advanced practice providers in neurology and primary care.

Program Overview

Early and accurate diagnosis of Alzheimer’s disease (AD) allows for patients to receive care earlier in the disease, which is especially important in the current landscape of emerging disease-modifying therapies (DMTs) for AD. The incorporation of biomarkers can further augment the diagnostic process to aid in earlier diagnosis of AD and prompt therapeutic intervention. In this educational podcast, join faculty Richard S. Isaacson, MD, and Charles P. Vega Jr, MD, as they provide an expert review on the association between biomarkers and clinical symptoms of AD, the use of biomarkers for early detection of AD, and the use of available and emerging DMTs for AD.

Learning Objectives

Upon completion of this activity, learners should be better able to:

  • OUTLINE the temporal association between AD neuropathological markers and clinical symptoms for early recognition and staging of AD
  • IMPLEMENT validated fluid and imaging biomarkers for the early detection of AD neuropathology
  • ASSESS the potential of available and emerging DMTs for AD according to their clinical efficacy, safety, and mechanism of action

 

Faculty

Richard S. Isaacson, MD (Chair)

Adjunct Associate Professor
Department of Neurology
Weill Cornell
New York, NY
Director, Center for Brain Health
Director, Alzheimer’s Prevention Clinic
Schmidt College of Medicine
Florida Atlantic University
Boca Raton, FL

Richard S. Isaacson, MD, serves as Director of the Center for Brain Health and Director of the Alzheimer’s Prevention Clinic (APC) at Florida Atlantic University’s Charles E. Schmidt College of Medicine in Boca Raton. He previously served as Director of the APC at the Weill Cornell Memory Disorders Program, Assistant Dean of Faculty Development, and Associate Professor of Neurology at Weill Cornell Medicine & NewYork-Presbyterian. He remains as Adjunct Associate Professor of Neurology in the Department of Neurology at Weill Cornell. Prior to that, Dr Isaacson served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. He completed his residency in Neurology at Beth Israel Deaconess Medical Center/Harvard Medical School, and his medical internship at Mount Sinai Medical Center in Miami Beach, FL. Prior to joining UM, Dr Isaacson served as Associate Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai.

A graduate of the accelerated 6-year BA/MD program at the University of Missouri - Kansas City School of Medicine, Dr Isaacson specializes in Alzheimer’s disease (AD) risk reduction in patients with no cognitive complaints and a family history of the disease, and pre-clinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia may be an important strategy for optimizing cognitive function and reducing dementia risk. Dr Isaacson has published novel methods on using a precision medicine approach in real-world clinical practice of AD risk reduction. He served as principal investigator (PI) for the APC Comparative Effectiveness Dementia & Alzheimer’s study, and has served as PI and/or co-investigator on a myriad of past grants related to AD prevention, treatment, and education. He has also focused on using whole genome sequencing to assess polygenic risk and further refine care.

Dr Isaacson previously served as Neurology Residency (12 years) and Clerkship Director (5 years), and his career in education spans undergraduate (student), graduate (resident/fellow), and continuing (faculty) medical education, as well as patient, caregiver, and community education/outreach. He led the development of Alzheimer’s Universe (AlzU.org), a vast online education research portal on AD (> 2 million unique visitors since 2014), with results published in the Journal of the Prevention of Alzheimer’s Disease, Journal of Communication in Healthcare, Alzheimer’s & Dementia: Translational Research & Clinical Interventions, and Neurology. Dr Isaacson served as Chair of the American Academy of Neurology (AAN) e-Learning Subcommittee where he has led a video education interview series in collaboration with Neurology Today on COVID-19, and helped to launch the bimonthly “NeuroBytes” online video-based education program. He also directed a multi-institution e-Learning collaboration on Faculty Development (wcmfd.org), led several online education research projects (including a CME course on AD risk reduction via AlzU.org/CME, and brain health courses in partnership with comedic actor Seth Rogen for high school, college, and medical students via AlzU.org/HFCU, which was published in Neurology), chaired the AAN Undergraduate Education Subcommittee working group in dementia, and received the AAN Education Research Grant for “Evaluating the effectiveness of Continuum: Dementia as a teaching tool for medical students”, also published in Neurology. In 2012, he led a collaborative education and health information technology research initiative at Weill Cornell, Harvard, UM, U. Pennsylvania, and U. Rochester published in Neurology. Dr Isaacson believes that through effective medical communication strategies, harnessing the broad reach of online, print, and broadcast media can be an exceptional tool to disseminate information in Neurology and Medicine. He has been quoted in hundreds of news stories and featured by major television (including ABC, CBS, NBC, CNN, and FOX) and print (such as the Wall Street Journal, the New York Times, AARP, Discover, O, and Reader’s Digest) outlets, including cover stories on the 2016 US News & World Report Best Hospitals Edition, Psychology Today, and others, totaling over 300 million impressions.

With a robust clinical practice and broad background in computer science, m-Health, biotechnology, and web development, Dr Isaacson is committed to using technology and comprehensive physical and cognitive assessments to optimize patient care, AD risk assessment, and early intervention. Leading distinct, yet interwoven, clinical research and technology teams, the APC has studied digital biomarkers using a wearable biosensor, and is committed to rigorously evaluating the effects of personalized, evidence-based multi-modal interventions on cognition, serum/radiologic biomarkers of AD and calculated AD, and cardiovascular risk. Considering his family history, including his Uncle Bob (diagnosed with AD while he was in high school) and his dad’s cousin (diagnosed over 10 years ago), he passionately believes in a comprehensive approach toward both AD treatment and prevention. Dr Isaacson is the author of numerous publications, his research in neurology and medical education has been presented at scientific meetings nationally and internationally, and he was awarded the 2009 AAN A.B. Baker Teacher Recognition Award. He is also a member of the Alpha Omega Alpha Medical Honor Society.

Charles P. Vega Jr, MD

Health Sciences Clinical Professor of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Executive Director
UC Irvine Program in Medical Education for the Latino Community
Irvine, CA

Dr Charles P. Vega Jr is Health Sciences Clinical Professor of Family Medicine and Assistant Dean for Culture and Community Education at the University of California (UC), Irvine, School of Medicine. He also serves as Executive Director of the UC Irvine Program in Medical Education for the Latino Community (PRIME-LC). Dr Vega earned his medical degree from the University of Wisconsin in Madison before completing a family medicine residency at UC Irvine. Additionally, he is a Fellow of the American Academy of Family Physicians. Dr Vega’s academic interests are focused on access to quality, compassionate medical care for underserved populations, and the development of training programs to promote this vision of health care. In 2014, he was awarded a Macy Faculty Scholarship to improve patient-centered health education at UC Irvine. Dr Vega has been invited to present at over 200 regional and national conferences on medical topics, medical education, and diversity and cultural effectiveness. He has authored over 1000 continuing medical education reviews and is a member of the California Medical Association, National Hispanic Medical Association, the American Academy of Family Physicians, and the California Academy of Family Physicians. Dr Vega serves on the editorial boards of the Journal of Family Practice and Women’s Health, and the Family Medicine Advisory Board of Medscape, Inc. He is also a reviewer for the Journal of the American Board of Family Medicine and American Family Physician.

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement:
Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. To receive CME credit participants must:

  • Read the objectives, disclosures and other introductory CME information
  • Complete the preassessment prior to the start of the activity
  • Participate in the activity
  • Submit the postassessment and evaluation at the conclusion of the activity
  • Receive a passing score of at least 80% on the postassessment
  • Certificates will be available to download and emailed to participants upon completion of of the activity

If you are seeking credit, you must complete the evaluation at the conclusion of the activity.

For information about the accreditation of this activity, please contact Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) at cme@montefiore.org or 718-920-6674.

For issues with your CME Certificate, please contact FreeCME at customerservice@reliasmedia.com.

Disclosures of Conflicts of Interest

The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All relevant financial relationships and potential conflicts of interest have been mitigated.

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

FACULTY
Richard S. Isaacson, MD (Chair)
Adjunct Associate Professor
Department of Neurology
Weill Cornell
New York, NY
Director, Center for Brain Health
Director, Alzheimer’s Prevention Clinic
Schmidt College of Medicine
Florida Atlantic University
Boca Raton, FL

Disclosures:
Dr. Isaacson has no relevant financial relationship with any ACCME-defined ineligible company in the past 24 months.

Charles P. Vega Jr, MD
Health Sciences Clinical Professor of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Executive Director
UC Irvine Program in Medical Education for the Latino Community
Irvine, CA

Disclosures:
Dr. Vega has no relevant financial relationship with any ACCME-defined ineligible company in the past 24 months.

EDUCATIONAL PLANNING COMMITTEE
Spire Learning
Ashton Webb, PharmD, BCACP (Clinical Director), Mairead Early (Program Manager), Allison Goldberg, MPA (Senior Director, Grants and Education), have no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

David M. Kaufman, MD (Peer Reviewer)
Professor, The Saul R. Korey Department of Neurology
Professor, Department of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Disclosure:
Dr Kaufman has no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Victor B. Hatcher, PhD (CME Reviewer)
Professor of Biochemistry and Medicine
Associate Dean, Continuing Professional Development
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Disclosure:
Dr Hatcher has no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Disclosure of Unlabeled Use

This educational activity does not contain discussion of unlabeled and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Privacy Policy

Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you. Additional information regarding Albert Einstein College of Medicine-Montefiore Medical Center’s Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx.

Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, address, phone number and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.

Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

Copyright Information

Copyright © 2022 by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning, LLC. All rights reserved including translation into other languages. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning, LLC.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above